GlassScriptPhysician profile
James J Spadaro
NPI 1063411999
$1,166.17
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $417 · 2021: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $183.54 | 2019-2021 | |
| Amarin Pharma, INC. | $168.09 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $115.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.97 | 2019-2021 | |
| Amgen INC. | $67.58 | 2019 | |
| Philips North America LLC | $67.00 | 2020 | |
| Abbott Laboratories | $64.01 | 2020 | |
| Pfizer INC. | $58.55 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.11 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.47 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $40.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.86 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.70 | 2019 | |
| Lundbeck LLC | $31.58 | 2019-2020 | |
| Esperion Therapeutics, INC. | $29.12 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $28.13 | 2019 | |
| Abiomed | $20.60 | 2020 | |
| Irhythm Technologies, INC. | $19.03 | 2019 | |
| Merck Sharp & Dohme LLC | $16.02 | 2021 | |
| Boston Scientific Corporation | $14.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Spadaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.